Associated Papers
ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.
Damaj G et al.
Plos One, 2014
24465546 (PubMed )
Supplement: pone.0085362.s001.pdf
ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.
Schnittger S et al.
Leukemia, 2013
Select a paper to view details